VIM and carcinoma: In this study, we demonstrated that Trametinib, a MEK1/2 signaling cascade inhibitor that is clinically employed to treat carcinoma (Gandara et al., 2017; Chesnokov et al., 2021; Jiang et al., 2022), holds great potential as a laboratory chemical for remodeling cytoskeletal vimentin network in living cells (Figure 4E).